Skip to main content

Nurix Therapeutics Short Interest Ratio and Short Volume

-0.12 (-0.46 %)
(As of 05/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume212,507 shs
Average Volume455,784 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A

Short Interest

Nurix Therapeutics (NASDAQ:NRIX) Short Interest Data

Current Short Volume4,420,000 shares
Previous Short Volume4,330,000 shares
Change Vs. Previous Month+2.08%
Dollar Volume Sold Short$132.56 million
Short Interest Ratio / Days to Cover8.6
Last Record DateApril, 15 2021
Outstanding Shares44,347,000 shares
Float Size25,190,000 shares
Short Percent of Float17.55%
Today's Trading Volume212,507 shares
Average Trading Volume455,784 shares
Today's Volume Vs. Average-53.38%

Short Interest Over Time

Nurix Therapeutics (NASDAQ:NRIX) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/15/20214,420,000 shares $132.56 million +2.1%17.6%8.6 $29.99
3/31/20214,330,000 shares $122.63 million +60.4%19.2%8.5 $28.32
3/15/20212,700,000 shares $119.23 million +6.7%13.1%5.8 $44.16
2/26/20212,530,000 shares $84.55 million +7.7%16.7%7.1 $33.42
2/12/20212,350,000 shares $91.58 million +22.4%15.5%7.8 $38.97
1/29/20211,920,000 shares $72.06 million +5.5%9.5%7.2 $37.53
1/15/20211,820,000 shares $77.62 million No Change9.0%8.4 $42.65

Nurix Therapeutics (NASDAQ:NRIX) Short Interest FAQ

speech bubbles
speech bubbles

What is Nurix Therapeutics' current short interest?

Short interest is the volume of Nurix Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 4,420,000 shares of NRIX short. 17.55% of Nurix Therapeutics' shares are currently sold short. View details.

What is a good short interest ratio for Nurix Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Nurix Therapeutics currently has a short interest ratio of 9.0.

What is a good short interest percentage for Nurix Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.55% of Nurix Therapeutics' floating shares are currently sold short.

Is Nurix Therapeutics' short interest increasing or decreasing?

Nurix Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 4,420,000 shares, an increase of 2.1% from the previous total of 4,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Nurix Therapeutics' float size?

Nurix Therapeutics currently has issued a total of 44,347,000 shares. Some of Nurix Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Nurix Therapeutics currently has a public float of 25,190,000 shares.

How does Nurix Therapeutics' short interest compare to its competitors?

17.55% of Nurix Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Nurix Therapeutics: Abcam plc (0.00%), Seer, Inc. (10.36%), BioAtla, Inc. (12.85%), Kinnate Biopharma Inc. (6.51%), Silverback Therapeutics, Inc. (11.23%), iTeos Therapeutics, Inc. (5.25%), Pharming Group (0.00%), 4D Molecular Therapeutics, Inc. (3.28%), 22nd Century Group, Inc. (0.00%), and Sigilon Therapeutics, Inc. (4.02%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.85 billion), Aon plc ($5.61 billion), Charter Communications, Inc. ($5.44 billion), Snap Inc. ($3.49 billion), Airbnb, Inc. ($3.35 billion), Peloton Interactive, Inc. ($2.53 billion), ViacomCBS Inc. ($2.48 billion), Expedia Group, Inc. ($2.39 billion), The Kroger Co. ($2.26 billion), and Nuance Communications, Inc. ($2.18 billion). View all of the most shorted stocks.

What does it mean to sell short Nurix Therapeutics stock?

Short selling NRIX is an investing strategy that aims to generate trading profit from Nurix Therapeutics as its price is falling. Nurix Therapeutics' stock is trading down $0.12 today. To short Nurix Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Nurix Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Nurix Therapeutics?

A short squeeze for Nurix Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NRIX, which in turn drives the price of the stock up even further.

How often is Nurix Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NRIX, twice per month. The most recent reporting period available is April, 15 2021.

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.